AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19135958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignatia homeopathic 30C
Number of subjects: 30
Study 19135958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17569404 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05% for 5 minutes
Number of subjects: 55
Study 17569404 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05% for 10 minutes
Number of subjects: 55
Study 17569404 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate vehicle for 10 minutes
Number of subjects: 55
Study 17569404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole foaming gel 2% for 5 minutes
Number of subjects: 55
Study 15186234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-optic broad-band UVB comb, treated three times a week for up to 12 weeks
Number of subjects: 14
Study 15186234 — intervention group
Group type: COMPARATOR
Intervention: Control area (minimum 50-cm² scalp area)
Number of subjects: 14
Study 11156490 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional index for hand osteoarthritis (FIHOA)
Number of subjects: 261
Study 11156490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain on visual analog scale (VAS)
Number of subjects: 261
Study 11156490 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning stiffness duration
Number of subjects: 261
Study 11156490 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 261
Study 9298686 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 100 IU
Number of subjects: 83
Study 9298686 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 83
Study 1622175 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg) administered orally and intravenously
Number of subjects: 12
Study 1622175 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no specific intervention mentioned)
Number of subjects: 12
Study 4083568 — intervention group
Group type: EXPERIMENTAL
Intervention: CL 115,347 (1000 mcg)
Number of subjects: 0
Study 4083568 — intervention group
Group type: EXPERIMENTAL
Intervention: CL 115,347 (500 mcg and 1500 mcg)
Number of subjects: 0
Study 4083568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31250668 — intervention group
Group type: EXPERIMENTAL
Intervention: DOT‐HTN
Number of subjects: 20
Study 31250668 — intervention group
Group type: COMPARATOR
Intervention: Standard ABPM
Number of subjects: 20
Study 31250668 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS assessment
Number of subjects: 20
Study 29106448 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH enoxaparin (1 mg/kg)
Number of subjects: 390
Study 29106448 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 390
Study 26216477 — intervention group
Group type: COMPARATOR
Intervention: 0 g GAA/kg diet
Number of subjects: 520
Study 26216477 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g GAA/kg diet
Number of subjects: 520
Study 26216477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g GAA/kg diet
Number of subjects: 520
Study 26216477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g GAA/kg diet
Number of subjects: 520
Study 26216477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g GAA/kg diet with 0 g ARG/kg diet
Number of subjects: 520
Study 26216477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g GAA/kg diet with 3 g ARG/kg diet
Number of subjects: 520
Study 26216477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g GAA/kg diet with 6 g ARG/kg diet
Number of subjects: 520
Study 26216477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g GAA/kg diet with 9 g ARG/kg diet
Number of subjects: 520
Study 25209897 — intervention group
Group type: EXPERIMENTAL
Intervention: Model OA consultation (MOAC) implementing NICE OA guidelines
Number of subjects: 0
Study 25209897 — intervention group
Group type: EXPERIMENTAL
Intervention: Model OA consultation (MOAC)
Number of subjects: 0
Study 25209897 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for GPs and practice nurses
Number of subjects: 0
Study 25209897 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 0
Study 22414507 — intervention group
Group type: EXPERIMENTAL
Intervention: Glazed zirconia
Number of subjects: 40
Study 22414507 — intervention group
Group type: COMPARATOR
Intervention: Ground, finished, and polished zirconia
Number of subjects: 40
Study 20576829 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hemodialysis training
Number of subjects: 0
Study 17150221 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20mg every other day)
Number of subjects: 36
Study 17150221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15871847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg o.i.d. combined with diet)
Number of subjects: 20
Study 15871847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15871847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 20
Study 12970285 — intervention group
Group type: EXPERIMENTAL
Intervention: r-human chorionic gonadotropin (r-hCG) 250 microg (n = 11)
Number of subjects: 40
Study 12970285 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant luteinizing hormone (r-LH) 1 mg (n = 13)
Number of subjects: 40
Study 12970285 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin; 0.2 mg) (n = 15)
Number of subjects: 40
Study 10757272 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand follow-up by a specialist nurse (NG)
Number of subjects: 400
Study 10757272 — intervention group
Group type: COMPARATOR
Intervention: Traditional follow-up by a urologist (UG)
Number of subjects: 400
Study 8854470 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with flutter VRP1 device
Number of subjects: 20
Study 8854470 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (control group)
Number of subjects: 20
Study 1524143 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets
Number of subjects: 261
Study 1524143 — intervention group
Group type: COMPARATOR
Intervention: Untreated nets
Number of subjects: 261
Study 427002 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg i.v. pindolol
Number of subjects: 0
Study 427002 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pindolol (5, 10, and 20 mg)
Number of subjects: 0
Study 427002 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31655883 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 55
Study 31655883 — intervention group
Group type: COMPARATOR
Intervention: Local corticosteroid injection (LCI)
Number of subjects: 55
Study 30116006 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg ondansetron
Number of subjects: 53
Study 30116006 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-mg ondansetron
Number of subjects: 53
Study 30116006 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-mg ondansetron
Number of subjects: 53
Study 30116006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 27471856 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation (single dose of 50,000 international units within 48-72 hours after birth)
Number of subjects: 11028
Study 27471856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsules)
Number of subjects: 11028
Study 27471856 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation
Number of subjects: 11028
Study 27471856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11028
Study 25552328 — intervention group
Group type: EXPERIMENTAL
Intervention: 2:1 mixture of 9 mg/ml propofol and 4.5 mg/ml ketamine (Group 1)
Number of subjects: 80
Study 25552328 — intervention group
Group type: COMPARATOR
Intervention: 4:1 mixture of 9 mg/ml propofol and 2.25 mg/ml ketamine (Group 2)
Number of subjects: 80
Study 23995982 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated patients
Number of subjects: 170
Study 23995982 — intervention group
Group type: COMPARATOR
Intervention: Non-isolated patients
Number of subjects: 170
Study 21351838 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release vaginal dinoprostone pessary
Number of subjects: 52
Study 21351838 — intervention group
Group type: COMPARATOR
Intervention: Vaginal dinoprostone gel
Number of subjects: 52
Study 19135574 — intervention group
Group type: EXPERIMENTAL
Intervention: Carra/LNG gel (0.75 mg in 4 mL) with sexual intercourse after 2-4 hours
Number of subjects: 12
Study 19135574 — intervention group
Group type: COMPARATOR
Intervention: Carra/LNG gel (0.75 mg in 4 mL) with abstinence
Number of subjects: 12
Study 17339186 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH 180 UI/Kg x 2/day s.c.
Number of subjects: 43
Study 17339186 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 100 UI/Kg x 2/day s.c.
Number of subjects: 43
Study 16321141 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of water
Number of subjects: 9
Study 16321141 — intervention group
Group type: COMPARATOR
Intervention: 50 ml of water (control)
Number of subjects: 9
Study 14616202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque 270 mg I/ml)
Number of subjects: 352
Study 14616202 — intervention group
Group type: COMPARATOR
Intervention: Iomeprol (Iomeron 300 mg I/ml)
Number of subjects: 352
Study 10363854 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics
Number of subjects: 73
Study 10363854 — intervention group
Group type: COMPARATOR
Intervention: IV antibiotics
Number of subjects: 73
Study 10363854 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient care
Number of subjects: 73
Study 10363854 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 73
Study 8614310 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienols (Palm Vitee)
Number of subjects: 50
Study 8614310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2269032 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) 120 mg four times a day
Number of subjects: 80
Study 2269032 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 80
Study 2269032 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 80
Study 2269032 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 80
Study 6969194 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid 200 mg t.d.s.
Number of subjects: 100
Study 6969194 — intervention group
Group type: COMPARATOR
Intervention: aspirin 600 mg t.d.s.
Number of subjects: 100
Study 29800130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of nitric oxide (iNO) at 80 parts-per-million for 4 hours after percutaneous revascularization
Number of subjects: 250
Study 29800130 — intervention group
Group type: COMPARATOR
Intervention: Control group inhaling oxygen without nitric oxide (CON)
Number of subjects: 250
Study 29800130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of nitric oxide (iNO)
Number of subjects: 250
Study 27062174 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.4mg/kg
Number of subjects: 160
Study 27062174 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 160
Study 24517173 — intervention group
Group type: COMPARATOR
Intervention: Personalized oxycodone dosing based on CYP2D6 phenotype testing and clinical pharmacokinetics.
Number of subjects: 15
Study 24517173 — intervention group
Group type: COMPARATOR
Intervention: CYP2D6 phenotype testing and pharmacokinetics analysis.
Number of subjects: 15
Study 23145765 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment together with Western standard treatment for 2 weeks plus secondary prevention treatment for 22 weeks
Number of subjects: 328
Study 23145765 — intervention group
Group type: COMPARATOR
Intervention: Western standard treatment for 2 weeks and secondary prevention treatment for 22 weeks
Number of subjects: 328
Study 20724673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health worker home visit
Number of subjects: 234
Study 20724673 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 234
Study 17976537 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 30
Study 17976537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15772469 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Insuflow device (warmed and humidified intraperitoneal gases)
Number of subjects: 50
Study 15772469 — intervention group
Group type: COMPARATOR
Intervention: Control group (room temperature insufflation gases)
Number of subjects: 50
Study 12441803 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) arm
Number of subjects: 183
Study 12441803 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 183
Study 12441803 — intervention group
Group type: EXPERIMENTAL
Intervention: TDM arm
Number of subjects: 183
Study 10625114 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptics combined with vitamin E (600 IU/day) for two weeks
Number of subjects: 39
Study 10625114 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptics alone
Number of subjects: 39
Study 8749696 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary beta 2‐microglobulin excretion > 500 ng/min
Number of subjects: 30
Study 8749696 — intervention group
Group type: COMPARATOR
Intervention: Urinary beta 2‐microglobulin excretion < or = 500 ng/min
Number of subjects: 30
Study 2290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Written health education
Number of subjects: 100
Study 2290769 — intervention group
Group type: COMPARATOR
Intervention: Control group (no written health education)
Number of subjects: 100
Study 6793053 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate and fentanyl
Number of subjects: 200
Study 6793053 — intervention group
Group type: COMPARATOR
Intervention: Halothane or morphine plus nitrous oxide
Number of subjects: 200
Study 30629458 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid supplementation (5 g/d)
Number of subjects: 20
Study 30629458 — intervention group
Group type: COMPARATOR
Intervention: Control (sunflower oil, isoenergetic quantity)
Number of subjects: 20
Study 28575932 — intervention group
Group type: EXPERIMENTAL
Intervention: Firewood/Kerosene stove users (Group A)
Number of subjects: 96
Study 28575932 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioethanol stove users (Group B)
Number of subjects: 96
Study 28575932 — intervention group
Group type: COMPARATOR
Intervention: Chicago women (Control Group C)
Number of subjects: 96
Study 25529189 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortoiliac stent (AIS) placement
Number of subjects: 68
Study 25529189 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 68
Study 23657892 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation
Number of subjects: 49
Study 21874390 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical navigation group (50 TKAs)
Number of subjects: 97
Study 21874390 — intervention group
Group type: COMPARATOR
Intervention: Standard technique group (50 TKAs)
Number of subjects: 97
Study 19470176 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and strength training program (3 weekly sessions for 8 weeks, 45-50 min each) focusing on muscular strength (leg press at 30% to 70% 1RM) and aerobic exercises (cycle-ergometry for 3-15 minutes at 12-14 RPE)
Number of subjects: 60
Study 19470176 — intervention group
Group type: COMPARATOR
Intervention: Usual care (general physical activity guidelines)
Number of subjects: 60
Study 17426181 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D immune globulin (WinRho SDF), 50 microg/kg (250 IU/kg) intravenously
Number of subjects: 47
Study 17426181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 15478853 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy
Number of subjects: 0
Study 15478853 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 0
Study 15478853 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapies
Number of subjects: 0
Study 15478853 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic therapy
Number of subjects: 0
Study 11092281 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg pioglitazone
Number of subjects: 408
Study 11092281 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 408
Study 11092281 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg pioglitazone
Number of subjects: 408
Study 11092281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 9091801 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg orally every 12 hours for five days)
Number of subjects: 220
Study 9091801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 9091801 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 220
Study 8371190 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical APF gel (1.2% F‐) with daily use of placebo mouthrinse (Group B)
Number of subjects: 466
Study 8371190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated mouthrinse daily, ACT (0.05% F‐) (Group C)
Number of subjects: 466
Study 8371190 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse daily (Group A)
Number of subjects: 466
Study 3079649 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin (CT) 100 MRC units injected i.m. every other day
Number of subjects: 0
Study 3079649 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 0
Study 31176287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity low-amplitude lumbar spinal manipulation (SMT)
Number of subjects: 80
Study 31176287 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 80
Study 30155761 — intervention group
Group type: EXPERIMENTAL
Intervention: Betalain-rich beetroot concentrate (BLN) 100 mg/day
Number of subjects: 28
Study 30155761 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 28
Study 26405104 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for trachoma grading (single day didactic training)
Number of subjects: 8
Study 25493942 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP + Fe (5 mg zinc, 12.5 mg iron)
Number of subjects: 28
Study 25493942 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP - Fe (5 mg zinc)
Number of subjects: 28
Study 25493942 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo powder)
Number of subjects: 28
Study 21621382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy (TE) + adenoidectomy
Number of subjects: 67
Study 21621382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillotomy (TT) + adenoidectomy
Number of subjects: 67
Study 21621382 — intervention group
Group type: COMPARATOR
Intervention: Control group (before surgery)
Number of subjects: 67
Study 21621382 — intervention group
Group type: COMPARATOR
Intervention: Control group (after surgery)
Number of subjects: 67
Study 20040148 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling sessions and follow-up telephone calls
Number of subjects: 72
Study 20040148 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study 18339792 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) levels during acute exacerbation
Number of subjects: 208
Study 18339792 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) levels in patients requiring ICU treatment
Number of subjects: 208
Study 18339792 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels predicting the need for ICU care
Number of subjects: 208
Study 18339792 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels predicting short-term mortality
Number of subjects: 208
Study 18339792 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels predicting long-term mortality
Number of subjects: 208
Study 15735109 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose of iron (DI)
Number of subjects: 313
Study 15735109 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose of multiple micronutrients (DMM)
Number of subjects: 313
Study 15735109 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dose of multiple micronutrients
Number of subjects: 313
Study 15735109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 313
Study 12889590 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (metronidazole plus erythromycin)
Number of subjects: 0
Study 12889590 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 10617955 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg elemental Zn/d
Number of subjects: 559
Study 10617955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 559
Study 8828534 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 ppm ozone exposure
Number of subjects: 15
Study 8828534 — intervention group
Group type: COMPARATOR
Intervention: Clean air exposure
Number of subjects: 15
Study 8828534 — intervention group
Group type: EXPERIMENTAL
Intervention: Both air and ozone exposures
Number of subjects: 15
Study 1425054 — intervention group
Group type: EXPERIMENTAL
Intervention: Diosmin (Daflon); 12 tablets in three divided doses for the first four days, then 2 tablets twice daily for another 10 days.
Number of subjects: 100
Study 1425054 — intervention group
Group type: COMPARATOR
Intervention: Placebo; same regimen as diosmin.
Number of subjects: 100
Study 3936108 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms IV infusion)
Number of subjects: 8
Study 3936108 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 30049236 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher vegetable protein consumption
Number of subjects: 2413